Investors / stance tracking
What Jeff Meechum is saying
FollowFollowingUnfollowOn CNBC (uncut), Oct 2026
3 dated public stances tracked since 2026-10-26, most recently 2026-10-26. Each line carries the date and the venue it came from; quotation marks mean verbatim. Methodology.
The stances below are c8alpha's editorial distillation of Jeff Meechum's public commentary — television, podcasts, and interviews — compiled by automated transcript analysis and dated to the episode they came from. They may lag the speaker's current view and may contain extraction errors. Text in quotation marks is verbatim from the episode; everything else is our paraphrase. Jeff Meechum is not affiliated with c8alpha and has not endorsed this page. Nothing here is investment advice.
Think we got something wrong? Report a misattribution — we correct it or take it down.
3
tracked stances
3
themes
0
side flips
2026-10-26
last heard
Most-argued themes
| Theme | Stances | Lean | Mix | Last |
|---|---|---|---|---|
| GILD | 1 | 1 bullish | 2026-10-26 | |
| LLY | 1 | 1 bullish | 2026-10-26 | |
| SMID-CAP BIOTECH | 1 | 1 bullish | 2026-10-26 |
Tracked stances
bullish / bearish is a view they argued; owns / short is a position they said they hold.
Medicare GLP-1 access starting July 1 provides a 3Q tailwind, with further upside from global oral GLP-1 rollout, a non-diabetes/obesity oral pipeline with low expectations, and Retatrutide (next-gen GLP-1) targeting a late-2027 launch
“Lilly comes to mind as probably one of the better performers that we expect, not just 3Q, but definitely 2027 and beyond”
CNBC uncut 2026-10-26 16:38 ET (5 min)
2026-10-26
SMID-CAP BIOTECH
bullish
CNBC (uncut) · uncut_tv
M&A consolidation cycle continues as large-cap pharma facing patent exclusivity losses seeks pipeline acquisitions among a robust cohort of phase-2-to-phase-3 maturing small and mid-caps, supported by healthy capital markets
“the market is not quite there yet, it doesn't feel over saturated at all”
CNBC uncut 2026-10-26 16:38 ET (5 min)
Gilead's HIV prevention drug YesTUGO is performing well and a next-gen blood cancer drug launching year-end sets up two product launches in H1 2027 that are not yet priced into the narrative
“I would look to Gilead Sciences. It's been one of our favorites for a while.”
CNBC uncut 2026-10-26 16:43 ET (5 min)
Idea Scout Weekly
Every Sunday: who said what across the tape we track — 1766 voices, 5,177 episodes and articles — with side-flips and points of disagreement called out. Free. How we track it.
Free · double opt-in · unsubscribe in one click